Clinical development

Rolf Karlsten M.D., Ph.D.
Rolf qualified as a medical doctor at Uppsala University hospital in 1982 and continued to work at the hospital as a senior consultant in anesthesiology until 2002 when he joined AstraZeneca. At AstraZeneca he worked as medical/scientific lead within the analgesia portfolio working throughout the portfolio from discovery to the clinical development strategies. His work was primarily from early discovery to Ph IIb with several targets, several indication areas including both small and large molecules. Rolf has worked through external Key Opinion Leader networks and acted as medical responsible at agency interactions within EU and US (FDA).

Matthias Rother M.D., Ph.D.
Matthias received his medical degree at Friedrich-Schiller University, Jena, Germany in 1984 and has since 1992 worked in different positions within clinical research with a broad range of responsibilities. He has a long-standing experience of design and management of Ph I-IV studies, non-interventional studies, and medical device clinical studies (various indications and classes). Matthias has had assignments within pharmacovigilance, preparing and executing medical plans including cross-functional development plans and interactions with medical agencies primarily EU and US (FDA). He has worked within several indication areas such as internal medicine, neurology/psychiatry and dermatology/allergology.